BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11193827)

  • 1. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.
    Drucker DJ; Lovshin J; Baggio L; Nian M; Adatia F; Boushey RP; Liu Y; Saleh J; Yusta B; Scrocchi L
    Ann N Y Acad Sci; 2000; 921():226-32. PubMed ID: 11193827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
    Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
    Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.
    Scrocchi LA; Marshall BA; Cook SM; Brubaker PL; Drucker DJ
    Diabetes; 1998 Apr; 47(4):632-9. PubMed ID: 9568697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.
    Drucker DJ
    Mol Endocrinol; 2003 Feb; 17(2):161-71. PubMed ID: 12554744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minireview: the glucagon-like peptides.
    Drucker DJ
    Endocrinology; 2001 Feb; 142(2):521-7. PubMed ID: 11159819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.
    Li Y; Cao X; Li LX; Brubaker PL; Edlund H; Drucker DJ
    Diabetes; 2005 Feb; 54(2):482-91. PubMed ID: 15677506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptides.
    Drucker DJ
    Diabetes; 1998 Feb; 47(2):159-69. PubMed ID: 9519708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut adaptation and the glucagon-like peptides.
    Drucker DJ
    Gut; 2002 Mar; 50(3):428-35. PubMed ID: 11839727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
    Sinclair EM; Drucker DJ
    Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.
    Brubaker PL; Drucker DJ
    Endocrinology; 2004 Jun; 145(6):2653-9. PubMed ID: 15044356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy.
    De León DD; Deng S; Madani R; Ahima RS; Drucker DJ; Stoffers DA
    Diabetes; 2003 Feb; 52(2):365-71. PubMed ID: 12540609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
    Baggio LL; Drucker DJ
    Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological actions and therapeutic potential of the glucagon-like peptides.
    Drucker DJ
    Gastroenterology; 2002 Feb; 122(2):531-44. PubMed ID: 11832466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Incretin research in the development of new strategies of diabetes therapy].
    Göke B; Göke R; Fehmann HC; Arnold R
    Internist (Berl); 1995 Apr; 36(4):343-9. PubMed ID: 7775082
    [No Abstract]   [Full Text] [Related]  

  • 20. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2.
    Munroe DG; Gupta AK; Kooshesh F; Vyas TB; Rizkalla G; Wang H; Demchyshyn L; Yang ZJ; Kamboj RK; Chen H; McCallum K; Sumner-Smith M; Drucker DJ; Crivici A
    Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1569-73. PubMed ID: 9990065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.